The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01F | Monoclonal antibodies and antibody drug conjugates | |
4
|
L01FX | Other monoclonal antibodies | |
5
|
L01FX23 |
| Active Ingredient |
|---|
|
Tisotumab vedotin is an antibody-drug conjugate (ADC) directed to tissue factor (TF), a cell surface protein expressed at elevated levels on a variety of solid tumours relative to normal tissue. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Tisotumab vedotin binds to TF-expressing tumour cells, the ADC-TF complex is internalised, and local release of MMAE occurs via proteolytic cleavage. MMAE disrupts the microtubule network of actively dividing cells, leading to cell cycle arrest and apoptotic cell death. |
| Document | Type | Information Source | |
|---|---|---|---|
| TIVDAK Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| TIVDAK Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.